Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Type 1 Diabetes Mellitus (T1DM)
91%
Type I Diabetes
84%
Diabetes
43%
Type 2 Diabetic Patients
35%
Chronic Kidney Disease
32%
Hemoglobin A1c (HbA1c)
28%
Denmark
27%
Glucagon-like
23%
Placebo
22%
Patients with Diabetes
18%
Confidence Interval
16%
Albuminuria
16%
Randomized Controlled Trial
14%
Cardiovascular Disease
14%
Obesity
13%
Liraglutide
13%
Estimated Glomerular Filtration Rate
13%
Diabetic Kidney Disease
13%
Cardiovascular Risk
13%
A1 Receptor
13%
Diabetes Management
12%
Glucagon
12%
Physical Activity
12%
Hypoglycemia
12%
Dapagliflozin
12%
Continuous Glucose Monitoring
12%
Hazard Ratio
11%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
11%
All-cause Mortality
11%
Receptor Agonist
11%
Finerenone
11%
Pre-diabetes (pre-DM)
11%
Glycemic Control
11%
Cardiovascular Mortality
11%
Body Mass Index
10%
Insulin
10%
Healthcare Professionals
10%
Meta-analysis
10%
Albumin-to-creatinine Ratio
10%
Randomized Placebo-controlled Trial
9%
Cardiovascular Outcomes
9%
AIMS™
8%
Metformin
8%
Microalbuminuria
8%
Glucose-dependent Insulinotropic Polypeptide
8%
Weight Loss
8%
Gestational Diabetes Mellitus
7%
Heart Failure
7%
High Risk
7%
Diabetes Duration
7%
Glucose-lowering Drugs
7%
Plasma Glucose
7%
Genome-wide Association Study
7%
Type 2 Diabetes Risk
7%
Risk Factors
7%
Hyperglycemia
6%
Randomized Clinical Trial
6%
Semaglutide
6%
Overweight or Obesity
6%
Blood Pressure
6%
Kidney
6%
Body Composition
6%
Insulin Resistance
6%
Kidney Function
6%
Insulin Sensitivity
6%
Cardiovascular Events
6%
Alzheimer's Disease
6%
Healthy Controls
6%
Greenland
5%
Incidence Rate
5%
Non-alcoholic Fatty Liver Disease (NAFLD)
5%
Oral Glucose Tolerance Test
5%
Copenhagen
5%
Gestational Diabetes
5%
Insulin Pump
5%
Kidney Disease
5%
Children with Type 1 Diabetes
5%
Type 2 Diabetes Prevention
5%
Without Diabetes
5%
Empagliflozin
5%
Kidney Outcomes
5%
Fasting Plasma Glucose
5%
Diabetic Nephropathy
5%
Lifestyle Intervention
5%
Medicine and Dentistry
Diabetes
70%
Maturity Onset Diabetes of the Young
68%
Insulin Dependent Diabetes Mellitus
59%
Cardiovascular System
28%
Placebo
23%
Chronic Kidney Disease
22%
Patient with Type 2 Diabetes
22%
Cardiovascular Disease
20%
Hemoglobin A1c
19%
Randomized Controlled Trial
13%
Cohort Analysis
13%
Albuminuria
11%
Hypoglycemia
11%
Body Mass Index
10%
Glomerular Filtration Rate
10%
Diabetic Nephropathy
9%
Diabetes Mellitus
9%
Disease
9%
Biological Marker
9%
Glucagon-Like Peptide-1 Agonist
9%
Prevalence
9%
Glycemic
9%
Kidney Function
9%
Glucagon Like Peptide 1
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Hazard Ratio
8%
Heart Failure
8%
Systematic Review
8%
Urinary System
7%
Creatinine
7%
Liraglutide
7%
Impaired Glucose Tolerance
7%
Semaglutide
7%
Glycon
7%
Glycemic Control
7%
Obesity
7%
Patient with Type 1 Diabetes
7%
Blood Pressure
7%
Hyperglycemia
7%
Nephropathy
7%
Gestational Diabetes
6%
Physical Activity
6%
Dapagliflozin
6%
Drug Therapy
6%
Cardiovascular Risk
6%
Insulin Pump
6%
Post-Hoc Analysis
6%
Gastric Inhibitory Polypeptide
5%
All Cause Mortality
5%
Glucagon
5%
Finerenone
5%
Clinical Trial
5%
Cross Sectional Study
5%
Meta-Analysis
5%
Body Weight
5%
Randomized Clinical Trial
5%
Microalbuminuria
5%
Quality of Life
5%
Autonomic Neuropathy
5%
Adverse Event
5%